Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatocellular Cancer: early-phase trial registry
8 of 16 indexed Hepatocellular Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 8 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Hepatocellular Cancer: 16 US clinical trials tracked, 8 recruiting.
Hepatocellular Cancer is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition hepatocellular-cancer
OPEN 8 | RECR 50% | LATE 1 | EARLY 10 | RANK #1060 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Hepatocellular Cancer lists 8 open slots (50% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatocellular Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatocellular Cancer is recruiting above its size-band peers.
8 of 16 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hepatocellular Cancer research.
National Cancer Institute (NCI) accounts for 3 of 16 trials (18.8%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatocellular Cancer enrolment sits around 94 participants.
Median target enrolment is 94 among the 16 trials that report a genuine target (sentinel values excluded). 9 of those (56.3%) plan for fewer than 100 participants.
-
Hepatocellular Cancer research is mostly interventional.
12 interventional and 4 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
University of Missouri-Columbia
NCT02838836
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
University of Missouri-Columbia
NCT03551951
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie
NCT06858813
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Montefiore Medical Center
NCT06899152
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Cancer Institute (NCI)
NCT05003895
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
The Methodist Hospital Research Institute
NCT05185505
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Jiping Wang, MD, PhD
NCT05701488
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Target PharmaSolutions
NCT02954094
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Exact Sciences Corporation
NCT05064553
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co.
NCT05438420
AFPᶜ³³²T in Advanced HCC
Adaptimmune
NCT03132792
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Cancer Institute (NCI)
NCT03937830
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
University of Michigan Rogel Cancer Center
NCT01522937
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT03195699
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
National Cancer Institute (NCI)
NCT01375569
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatocellular Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatocellular Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatocellular Cancer page
16 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Hepatocellular Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Hepatocellular Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatocellular Cancer condition card totals 16 registered trials; most-linked intervention Tremelimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.